PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Gastroenterology. Author manuscript; available in PMC 2011 December 1.
Published in final edited form as:
PMCID: PMC2997189
NIHMSID: NIHMS251886

Helicobacter pylori and esophageal disease: wake-up call?

The history of science is marked by the nature of discovery (1). Sometimes discoveries bias a field, and it takes a long time for the true directions to emerge. This concept is particularly relevant to microbiology, since most of the bacteria of which physicians are aware are pathogens and were discovered due to their link with disease; Mycobacterium tuberculosis, Vibrio cholerae, and Neisseria meningitis serve as examples. Yet most bacteria in the human body are commensals (2).

The discovery of Helicobacter pylori in 1979–1982 by Marshall and Warren was a major event in the field of gastroenterology, recognized in many ways including the awarding of the 2005 Nobel Prize in Medicine (3). The initial discoveries of H. pylori were as pathogen: an organism in the stomach that provoked an inflammatory response, called by pathologists “chronic gastritis,” and leading, as suspected by Marshall and Warren, to peptic ulceration (4,5), and as later determined, to increased risk for intestinal metaplasia, atrophic gastritis, and gastric adenocarcinoma (reviewed in 6). After a strong body of work over the following decade, H. pylori became established firmly as a human pathogen (7). In consequence, major pharmaceutical companies developed methods to ensure its eradication, and governmental agencies and foundations have sought ways to promote such strategies. Why not rid the world of a pathogen that clearly may lead to a serious and sometimes lethal disease, peptic ulceration, and to a very serious and common form of malignancy-gastric cancer? Indeed, why not?

However, all mammals, even marine mammals, appear to have helicobacters residing in their stomach (8,9), and there is no evidence that any mammalian acid-producing stomach has evolved without their presence. In particular, H. pylori has been colonizing the human stomach for at least 58,000 years, dating from the last out-of-Africa (10), and probably much, much longer. H. pylori traveled with us as we have migrated to all corners of the world during pre-history (11). What are the implications of an ancestral gastric microbial colonization conserved over 100 million years of mammalian evolution? Might there not be some costs associated with changing such a longstanding relationship?

In this issue of Gastroenterology, Sonnenberg and colleagues (12) report on a large study based on >78,000 US patients who had had upper gastrointestinal (UGI) endoscopy performed, and from whom histopathological analysis of gastric biopsies was done. The investigators sought to ascertain the relationships between the presence of H. pylori, chronic gastritis, and intestinal metaplasia with each other, and with Barrett’s esophagus. The results, reflecting the straightforward design and large scale of these studies, are clear-cut. All three findings by the pathologists- the presence of H. pylori, chronic gastritis, and intestinal metaplasia-were strongly correlated with each another, confirming many prior studies (13,14). However, Sonnenberg et al. showed that all three findings were also inversely associated with Barrett’s esophagus. The study was robust and internally consistent, so there is no doubt that the findings are correct. The important issue is how physicians, scientists, and patients should interpret these results.

Barrett’s esophagus is an intermediate lesion along the pathway between reflux esophagitis [also well-known as gastro-esophageal reflux disease (GERD)] and esophageal adenocarcinoma (15). As with other pathogenetic sequences, relatively many individuals have GERD, fewer have Barrett’s, and fewest develop EAC (15). Most importantly, GERD, Barrett’s, EAC, (and the closely related adenocarcinomas affecting the adjacent gastric cardia), each are increasing in epidemic proportions all over the developed world (1620), and EAC is a terrible and difficult-to-treat form of cancer. These conditions, one nested within the other, arose in the mid-to-late 20th century and are continuing to climb in incidence.

How do the findings of Sonnenberg et al. (12) relate to these events? Is there a causal relationship between the inverse association of H. pylori (and its related conditions), and Barrett’s (and its related conditions), and if so, in which direction (A→B, or B→A)? Alternatively, do the findings reflect an underlying process affecting the risk of both (thus, C→A and C→B), or are they just spurious? The large scale and internal consistency of the Sonnenberg study argue that the findings are not artifactual. In fact, their findings confirm and extend many other studies over the last decade showing parallel relationships in different populations, and using different techniques of ascertainment (2125). Although, the Sonnenberg study was not designed to address the vectors and direction of causality, it should now be clear to all impartial observers that there truly is a reciprocal relationship between H. pylori and Barrett’s.

How can the relationship be explained? Could GERD and related conditions be causing the loss of H. pylori? This is highly unlikely since GERD usually develops in adults but H. pylori is acquired in early childhood. Could the absence of H. pylori be pre-disposing to GERD? As most gastroenterologists know, once acquired, H. pylori colonization generally persists for life (26), unless interrupted by antibiotic treatment, or by the development of chronic atrophic gastritis very late in life. Thus, since time immemorial, H. pylori has persistently colonized most of the world’s population, essentially for their full lifetime (26), but in most cases, its presence leads to no symptoms. Indeed, when what we now know as H. pylori was recognized in the 19th century by German pathologists, it was essentially universal, and they concluded that it was not worth studying because it was a commensal.

During the 20th century and now into the 21st century, the prevalence of this ancestral common human bacterium has been undergoing a precipitous decline in developed countries. Now, fewer than 6% of US children are carrying the organism (27), and parallel phenomena are being observed across the developed world (28,29). Thus, over the course of a century, the ancient, persistent, nearly universal and dominant inhabitant (30,31) of the human stomach has been essentially disappearing. The reasons for its disappearance are manifold (32); regardless, its decline is continuing, and with effects throughout the world, while GERD and its sequelae are increasing (20). GERD was essentially first reported in the medical literature in the 1930’s (33), Dr. Norman Barrett first described metaplasia in the esophagus in the 1950s (34), and the rise in EAC began to occur in the 1970’s (17). All of these trends have occurred as H. pylori has been disappearing, and Sonnenberg et al. (12) provide yet more evidence that this is a linked association.

Interestingly, paralleling the inverse associations of H. pylori and esophageal disease have come multiple reports of inverse associations with childhood-onset asthma (27,35,36), and protection from other infections (37,38), or their reactivation (39). Since the stomach produces two hormones, leptin and ghrelin, centrally involved in human energy homeostasis (40,41), and H. pylori status affects their regulation (26,42), could lack of H. pylori in childhood be contributing to the worldwide epidemic of childhood onset obesity and diabetes?

Isn’t it time for gastroenterologists to think more broadly about the effect of an ecological extinction of major proportions occurring in our bodies? Since familial, and specifically maternal, carriage is important in the transmission of H. pylori to the next generation (43,44), it follows that this extinction affects not only us but our children and grandchildren.

Our relationships with our microbiota are not static, especially as we age; organisms that are pathogenic in old age might have been commensals or even symbionts earlier in life. Hosts respond to their commensals with both adaptive and innate effectors in the mucosa and lamina propria (4547); why are we using the term “chronic gastritis” to describe the gastric version of the ancient conserved responses to our endogenous microbiota, which in the stomach is predominantly H. pylori ? Many organisms that we already consider commensals are opportunistic pathogens (e.g. viridens streptococci, Candida albicans, and Klebsiella); we are not attempting to eradicate these organisms from everyone. The clear report of Sonnenberg et al. suggests that it is time to re-think the “why?” and “how?” about H. pylori and its relationship to humans.

Gastroenterologists must study the growing field of human microbial ecology to address the epidemics of today and to not be further propagating them. Ecology is complex, and H. pylori has a complex, deeply evolved biological relationship with humans. Simple approaches (48), like “test and treat” fail to appreciate this complexity. We clearly need to remove H. pylori from persons with peptic ulcer disease and from those who are at substantial risk for gastric cancer, but the latter is an important research frontier; we must understand from whom to eradicate H. pylori and when (6), before disease is inevitable. However, this is a relatively small segment of the overall population in most localities and is most relevant relatively late in life.

But if H. pylori protects our esophagus, our airways, and maybe our waistline, should we now begin thinking about giving it back in some form, especially to children, just as pediatricians give live vaccines of persistent microbes today? More than a decade ago, I speculated that doctors will be giving H. pylori to the children of the future (49,50). If we will someday do so, first we must have much deeper knowledge of H. pylori, so as to safely restore our ancient companion, maximizing benefit and minimizing risk, and to then be able to eradicate it from the right persons at the right time. Perhaps in such a way, we can curtail these growing epidemics, and before Mother Nature’s introduced H. pylori-replacements become our new dominant gastric bacteria, without the benefit of millennia of co-evolution and likely to be much less benign.

Footnotes

Conflict of Interest Statement:

Martin Blaser is a co-inventor of technologies developed at Vanderbilt University and NYU related to the diagnosis, prevention, and treatment of Helicobacter pylori infections and complications related to their presence or absence. There are no commercial applications at the present time, nor are any licensed.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Kuhn TS. The structure of scientific revolutions. The University of Chicago Press; Chicago IL: 1962. pp. 1–172.
2. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature. 2007;449:804–10. [PMC free article] [PubMed]
3. Marshall BJ, Warren JR. Nobel Prize. 2005. The bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease.
4. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–5. [PubMed]
5. Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5. [PubMed]
6. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev Cancer. 2002;2:28–37. [PubMed]
7. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65–69. [PubMed]
8. Harper CMG, Feng Y, Xu S. Helicobacter cetorum sp. nov. a urease-positive Helicobacter species isolated from dolphins and whales. J Clin Microbiol. 2002;40:4536–43. [PMC free article] [PubMed]
9. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev. 2001;14:59–97. [PMC free article] [PubMed]
10. Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, Falush D, Stamer C, Prugnolle F, van der Merwe SW, Yamaoka Y, Graham DY, Perez-Trallero E, Wadstrom T, Suerbaum S, Achtman M. An African origin for the intimate associate between humans and Helicobacter pylori. Nature. 2007;445:915–8. [PMC free article] [PubMed]
11. Moodley Y, Linz B, Yamaoka Y, Windsor HM, Breurec S, Wu JY, Maady A, Bernhoft S, Thiberge JM, Phuanukoonnon S, Jobb G, Siba P, Graham DY, Marsahll BJ, Achtman M. The peopling of the Pacific from a bacterial perspective. Science. 2009;323:527–30. [PMC free article] [PubMed]
12. Sonnenberg A, Lash RH, Genta RM. A national study of H. pylori infection in gastric biopsy specimens. Gastroenterology. 2010 in press. [PubMed]
13. Kuipers EJ, Pena AS, Meuwissen SGM, Uyterlinde AM, Roosendaal R, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345:1525–1528. [PubMed]
14. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001;134:380–6. [PubMed]
15. Shaheen N, Ransahoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287:1972–81. [PubMed]
16. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Eng J Med. 1999;340:825–831. [PubMed]
17. Devesa SS, Blot WJ, Fraumeni JF., Jr Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–53. [PubMed]
18. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. JNCI. 2005;97:142–46. [PubMed]
19. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549–55. [PubMed]
20. Bresalier RS. Barrett’s esophagus and esophageal adenocarcinoma. Ann Rev Med. 2009;60:221–231. [PubMed]
21. Chow W-H, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Pérez-Pérez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Research. 1998;58:588–590. [PubMed]
22. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. JNCI. 2004;96:388. [PubMed]
23. de Martel C, Llosa AE, Farr SM, et al. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis. 2005;191:761–7. [PubMed]
24. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res. 2008;1:329–38. [PMC free article] [PubMed]
25. Whiteman DC, Parmer P, Fahey P. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology. 2010;139:73–83. [PubMed]
26. Atherton JC, Blaser MJ. Co-adaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest. 2009;119:2475–87. [PMC free article] [PubMed]
27. Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis. 2008;198:553–60. [PMC free article] [PubMed]
28. Segal I, Otley A, Issenman R, Armstrong D, Espinosa V, Cawdron R, Morshed MG, Jacobson K. Low prevalence of Helicobacter pylori in Canadian children: a cross-sectional analysis. Can J Gastroenterol. 2008;22:485–89. [PMC free article] [PubMed]
29. Rothenbacher D, Bode G, Berg G, Gommel R, Gonser T, Adler G, Brenner H. Prevalence and determinants of Helicobacter pylori infection in preschool children: a population-based study from Germany. Int J Epidemiol. 1998;27:135–41. [PubMed]
30. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, Perez-Perez G, Blaser MJ, Relman DA. Molecular analysis of the bacterial microbiota in the human stomach. PNAS. 2006;103:732–737. [PubMed]
31. Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE. 2008;3:e2836. [PMC free article] [PubMed]
32. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nature Rev Microbiol. 2009;7:887–894. [PubMed]
33. Winkelstein A. Peptic esophagitis: a new clinical entity. JAMA. 1935;104:906–9.
34. Barrett NR. Chronic peptic ulcer of the oesophagus and “oesophagitis” Br J Surg. 1950;38:175–82. [PubMed]
35. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergies. Arch Intern Med. 2007;167:821–827. [PubMed]
36. Janson C. The effect of infection burden. J Allergy Clin Immunol. 2007;120:673–9. [PubMed]
37. Rothenbacher D, Blaser MJ, Bode G, Brenner H. An inverse relationship between gastric colonization by Helicobacter pylori and diarrheal illnesses in children: results of a population-based cross-sectional study. J Infect Dis. 2000;182:1446–49. [PubMed]
38. Chang AH, Haggerty TD, de Martel C, Leung CW, Parsonnet J. Effect of Helicobacter pylori infection on symptoms of gastroenteritis due to enterohepatic Escherichia coli in adults. Dig Dis Sci. 2010 in press. [PMC free article] [PubMed]
39. Perry S, de Jon BC, Solnick JV, De la Luz Sanchez M, Yang S, Lin PL, Hansen LM, Talat N, Hill PC, Hussain R, Adegbola RA, Flynn J, Canfield D, Parsonnet J. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS One. 2010;51:e8804. [PMC free article] [PubMed]
40. Mix H, Widjaja A, Jandl O, et al. Expression of leptin and leptin receptor isoforms in the human stomach. Gut. 2000;47:481–486. [PMC free article] [PubMed]
41. Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, Fugimiya M. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB Journal. 2004;18:439–56. [PubMed]
42. Nwokolo CU, Freshwater DA, O’Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut. 2003;52:637–40. [PMC free article] [PubMed]
43. Rothenbacher D, Winkler M, Gonser T, Adler G, Brenner H. Role of infected parents in transmission of Helicobacter pylori to their children. Pediat Infect Dis. 2002;21:674–9. [PubMed]
44. Nahar S, Kibria KM, Hossain ME, Sultana J, Sarker SA, Engstrand L, Bardhan PK, Rahman M, Endtz HP. Evidence of intra-familial transmission of Helicobacter pylori by PCR-based RAPD fingerprinting in Bangladesh. Eur J Clin Microbiol Infect Dis. 2009;28:767–73. [PubMed]
45. Pamer E. Immune responses to commensal and environmental microbes. Nat Immunol. 2007;8:1173–78. [PubMed]
46. Varol C, Zigmond E, Jung S. Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat Rev Immunol. 2010;10:415–26. [PubMed]
47. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10:159–69. [PubMed]
48. Graham D. The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet. 1997;350:71. [PubMed]
49. Blaser MJ. Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet. 1997;349:1020–1022. [PubMed]
50. Blaser MJ. Science, medicine, and the future: Helicobacter pylori and gastric diseases. Br Med J. 1998;316:1507–10. [PMC free article] [PubMed]